1. Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options J Am Coll Cardiol. 2016;67(11):1338-1357. doi:10.1016/j.jacc.2015.12.049 The Peripheral Artery Disease Prescription Management of patients with peripheral artery disease: recommendations for improving outcomes and quality of life. ACE = angiotensin-converting enzyme; CV = cardiovascular; MI = myocardial infarction. Figure Legend:

2. Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options J Am Coll Cardiol. 2016;67(11):1338-1357. doi:10.1016/j.jacc.2015.12.049 Adherence to Guideline-Recommended Medical Therapies and Outcomes in PAD Among patients with symptomatic peripheral artery disease (PAD) undergoing lower-extremity angiography, adherence to the guideline-recommended therapies of an antiplatelet agent, statin, angiotensin-converting enzyme inhibitor, and abstention from smoking is associated with a significant reduction in (A) major adverse cardiovascular events and (B) major adverse limb events. CI = confidence interval; PAD = peripheral artery disease. Figure Legend:

3. Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options J Am Coll Cardiol. 2016;67(11):1338-1357. doi:10.1016/j.jacc.2015.12.049 Limb-Related Events in Patients Treated With Vorapaxar In the TRA 2°P-TIMI 50 trial, patients randomized to vorapaxar had significantly lower rates of (A) acute limb ischemia and (B) peripheral revascularization. HR = hazard ratio. Figure Legend:

4. Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options J Am Coll Cardiol. 2016;67(11):1338-1357. doi:10.1016/j.jacc.2015.12.049 Relationship Between Target-Lesion Length and Patency in Comparative Femoral Popliteal Trials Figure Legend: